sign in sign up
<<
Home , Altretamine, Idelalisib, Porfimer sodium

New Drugs Reviewed by CPG January 23, 2017 (Original New Drug Applications: FDA) Generic Name Trade Name Indication(s) CPG Action Immune globulin Cuvitru Biologic and In accordance with subcutaneous Immunological the SCA [human] 20% solution Agents/Immune Globulins/ Immune Globulin (Human) subcutaneous. Indicated as replacement for primary humoral immunodeficiency in adult and pediatric patients age two and older. eteplirsen Exondys 51 Central Nervous System In accordance with Agents/Antisense the SCA Oligonucleotides. Treatment of patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping. First drug approved for reatment of patients with Duchenne muscular dystrophy. levonorgestrel- Kyleena Endocrine and May prescribe releasing intrauterine Metabolic Agents/sex system 19.5 mg homones/contraceptive Hormones. Prevention of pregnancy for up to five years. **Phentermine Lomaira Central Nervous System In accordance with hydrochloride 8 mg Agents/ the SCA anorexiants/sympathomi metic anorexiants. Short term use weight reduction in adults with **(new formulation at an initial BMI of 30 or lower dosage) more or 27 with at least one weight-related condition.

1 New Drugs January 2017 canaglifozin/ Invokamet XR Endocrine and May prescribe metformin HCL Metabolic Agents/ extended-release antidiabetic agents/antidiabetic combination products. Treatment of adults with type 2 diabetes as an adjunct to diet and exercise. Adalimumab-atto Amjevita Biologic and In accordance with Immunological Agents/ the SCA Immunologic Agents/Immunomodulat ors/Tumor necrosis Factor-Alpha Blockers. Indicated for treatment of adults with: rheumatoid arthritis, psoriatic arthritis,ankylosing spondylitis, Crohn disease, ulcerative , and plaque psoriasis. Also indicated for juvenile idiopathic arthritis in pts age 4 years and older. Flublok Quadravalent Biologic and May prescribe Immunological Agents/agents for active immunization/vaccines, viral. Protects against 4 straing of influence, 3 of the same strains found in trivalent Flublok as well as an additional B strain. Approved for adults age 18 and older.

2 New Drugs January 2017 olaratumab Lartuvo Antineoplastic May not prescribe Agents/monoclonal antibodies. For use in combination with for the treatment of adult patients with soft tissue sarcoma with a histologic subtype for which an - containing regiment is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. bezlotoxumab Zinplava Biologic and May prescribe Immuniclogical Agents/ monocolonal antibodies (biologic/immunologic). Reduces recurrence of C-diff infection in patients age 18 and older who are receiving antibacterial drug treatment of C-diff an are at high risk for recurrence. tenofovir alafenamide Vemlidy Anti-infective Agents/ May prescribe antiretroviral agents/nucleotide analog reverse transcriptase inhibitors. Treatment of chronic hepatitis B infection in adults with compensated liver disease. DHEA Intrarosa Endocrine and May prescribe Metabolic Agents/ sex homones. Treatment of postmenopausal moderate to severe dyspareunia.

3 New Drugs January 2017

Insulin Soliqua Endocrine and May prescribe glargine/lixisenatide Metabolic Agents/antidiabetic agents/insulin combination. Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes inadequately controlled on basal insulin or lixisenatide. SMOFlipid Nutrients and Nutritional May prescribe Agents/intravenous nutritional therapy/lipids. Source of calories, essential fatty acids, and omega-3 fatty acids for adults requiring parenteral nutrition. Eucrisa Crisaborole 2% Dermatological agents/ May prescribe phosphodiesterase-4 inhibitors. Topical treatment of mild to moderate atopic dermatitis in patients age 2 years and older. Rubraca Antineoplastic In accordance with Agents/PARP Enzymes the SCA Inhibitor. Approved for treatment of . nusinersen Spinraza Central Nervous System In accordance with Agents/Antisense the SCA Oligonucleotides. Treatment of spinal muscular atrophy.

4

New Drug Indications/ Warnings Reviewed by CPG January 23, 2017 (New Drug Indications/ Boxed Warnings: FDA)

Generic Name Trade Name Therapeutic Category CPG Action canakinumab Ilaris Biologic and Immunological Current: In Agents; immunologic agents; accordance with the (expanded indication) immunomodulators SCA

January 23, 2017: No change

ustekinumab Stelara Biologic and Immunological Current: In Agents;immunologic agents; accordance with the immunomodulators SCA (expanded indication) January 23, 2017: No change Zydelig Antineoplastic Agents; Kinase Current: May not Inhibitors; phosphatidylinositol 3- prescribe (expanded black box kinase inhibitors warning) January 23, 2017: No change

lumacaftor/ Orkambi Endocrine and Metabolic Agents; Current: In ivacaftor cystic fibrosis transmembrane accordance with the regulator protein SCA (expanded indication) January 23, 2017: No change

eltrombopag Promacta Hemotologic Agents; Current: In hematopoietic agents; accordance with the (expanded boxed thrombopoietin receptor agonist SCA warning) January 23, 2017: No change atezolizumab Tecentriq Antineoplastic agents; monoclonal Current: May not (expanded indication) antibodies (antineoplastic) prescribe

January 23, 2017: No change paricalcitol Zemplar Nutrients and Nutritional Agents; Current: May vitamins; fat-soluble vitamins; prescribe (expanded indication) vitamin D January 23, 2017: No change

1 New Drug Indications January 2017

pembrolizumab Keytruda Biologic and Immunological Current: May not Agents; immunologic agents; prescribe (expanded indication) immunomodulators January 23, 2017: No change etanercept Enbrel Biologic and Immunological Current: In Agents; immunologic agents; accordance with the immunomodulators; tumor SCA (expanded indication) necrosis factor-alpha blockers (TNF-alpha blockers) January 23, 2017: No change daratumumab Darzalex Antineoplastic Agents; Current: May not monoclonoal antibodies prescribe (expanded indication) (antineoplastic) January 23, 2017: No change flu vaccine FluLaval Biologic and Immunological Current: May Quadrivalent Agents/ Agents for Active prescribe (expanded indication) Immunization/vaccine, viral. January 23, 2017 No change sevelamer carbonate Renvela Renal and Genitourinary Agents/ Current: May Phosphate Binders. prescribe (expanded indication) January 23, 2017: No change empagliflozin Jardiance Endcrine and Metabolic Agents/ Current: May Antidiabetic Agents/ sodium- prescribe glucose co-transporter 2 (expanded indication) inhibitors. January 23, 2017: No change hyaluronic acid Restylane Central Nervous System Agents/ Current: May Refyne physical adjuncts/hyaluronic acid prescribe derivatives, dermal. (expanded indication) January 23, 2017: No change hyaluronic Acid Restylane Central Nervous System Agents/ Current: May Defyne physical adjuncts/hyaluronic acid prescribe derivatives, dermal. (expanded indication) January 23, 2017: No change degludec and Tresiba and Endocrine and Metabolic Agents/ Current: May degludec/insulin Ryzodeg 70/30 Antidiabetic Agents/Insulin. prescribe aspart (expanded indication) January 23, 2017: No change

2 New Drug Indications January 2017

chlorazepate Tranxene T- Central Nervous System Agents/ Current: may dipotassium Tab Benzodiazepines. prescribe

(boxed warning) January 23, 2017: No change temazepam Restoril Central Nervous System Agents/ Current: May Benzodiazepines. prescribe (boxed warning) January 23, 2017: No change tramadol Utram Central Nervous System Agents/ Current: May hydrochloride Opioid Analgesics. prescribe

(boxed warning) January 23, 2017: No change antihemophilic factor Adynovate Hemotological Current: In [recombinant], Agents/Antihemophilic accordance with the pegolated Agents/Antihemophilic Factor SCA (Factor VIII:AHF). (expanded indication) January 23, 2017: No change nalbuphine Nubain Central Nervous System Agents/ Current: May hydrochloride Opioid Agonist-Antagonist prescribe Analgesics. (boxed warning) January 23, 2017: No change Diazepam Valium Central Nervous System Agents/ Current: May Benzodiazepines. prescribe (boxed warning) January 23, 2017: No change oxymorphone Opana Central Nervous System Current: Subject to hydrochloride Agents/Opioid Analgesics. Schedule II restrictions/ (expanded indication) formulary

January 23, 2017: No change fentanyl citrate Fentanyl Central Nervous System Current: Subject to Agents/Opioid Analgesics. Subject to Scheduel (boxed warning) II restrictions/ formulary

January 23, 2017: No change pentazocine Talwin Central Nervous System Agents/ Current: May Opioid Agonist-Antagonist prescribe (boxed warning) Analgesics. January 23, 2017: No change

3 New Drug Indications January 2017

Merperidine Demerol Central Nervous System Agents/ Current: subject to hydrochloride Opioid Analgesics. Schedule II prescribing (boxed warning) restrictions/ formulary

January 23, 2017: No change chlordizepoxide Librium Central Nervous System Agents/ Current: May hydrochloride Benzodiazepines. prescribe

(boxed warning) January 23, 2017: No change empaglifozin/ Glyxambi Endocrine and Metabolic Agents/ Current: May Linagliptin Antidiabetic Agents/ Antidiabetic prescribe Combination products. (expanded indication) January 23, 2017: No change Sufentanil citrate Central Nervous System Current: subject to Agents/Opioid Analgesics. schedule II (boxed warning) prescribing restrictions/ formulary

January 23, 2017: No change oxycodone Percodan Central Nervous System Current: subject to hydrochloride/ Agents/Opioid Analgesic schedule II aspirin Combinations. prescribing restrictions/ (boxed warning) formulary

January 23, 2017: No change ranibizumab Lucentis Ophthalmic and Otic Agents/ Current: In Selective Vascular Endothelial accordance with the (expanded indication) Growth Factor Antagonists. SCA

January 23, 2017: No change

4

Formulary Revision Request January 23, 2017

Generic Name Trade Name Indication(s) CPG Action

Formulary Review Revision Requests from Beth Faiman et al, Cleveland Clinic Taussig Cancer Institute

(subcategories within multiple CPG Antineoplastic comprehensively Section) reviewed Kinase inhibitors individual drugs Proteasome Inhibitors within the Anti- Monoclonal neoplastic Section antibodies of the Formulary. Alkalating Agents See CPG Updates for prescribing parameter change for specific drugs.

Antimetabolite and multiple CPG substituted ureas comprehensively reviewed individual drugs within the Anti- neoplastic Section of the Formulary. See CPG Updates for prescribing parameter change for specific drugs.

Formulary Review Revision Request from Cindy Tudor, Cincinnati Children's Hospital Medical Center

Central Nervous System Current: CTP Vigabatrin Sabril Agents: Anticonvulsants holder may not (REMS Program) Infantile spasms: As prescribe monotherapy for pediatric patients 1 January 23, 2017: month to 2 years of age In accordance with with infantile spasms for the SCA whom the potential benefits outweigh the potential risk of vision loss. Refractory complex partial seizures: As

1 adjunctive therapy for adults and pediatric patients 10 years and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss.1

2

Review of Prescribing Designations In Accordance with Standard Care Arrangement and CTP Holder May NOT Prescribe Antineoplastic Agents (January 23, 2017)

Drug Name Antineoplastic Current CPG Action Subcategory Prescribing Designation

Busulfan Alkylating Agents/ May not January 23, Alkyl Sulfonates prescribe 2017: No change Alkylating Agents/ May not January 23, Sodium Estrogen/ prescribe 2017: No change Alkylating Agents/ May not January 23, (Hexamethylmelamine) Ethylenimines/Methylmelamines prescribe 2017: No change

Thiotepa Alkylating Agents/ May not January 23, (Triethylenethiophosphoramide Mechlorethamine Derivative prescribe 2017: No ; Tspa; Tespa) change

Altretamine Alkylating Agents/ May not January 23, (Hexamethylmelamine) Ethylenimines/Methylmelamines prescribe 2017: No change Hydrochloride Alkylating Agents/ May not January 23, Ethylenimines/Methylmelamine/ prescribe 2017: No Mechlorethamine Derivative change

Thiotepa Alkylating Agents May not January 23, (Triethylenethiophosphoramide Ethylenimines/Methylmelamines prescribe 2017: No ; Tspa; Tespa) change

Chlorambucil Alkylating Agents/ May not January 23, Nitrogen Mustards prescribe 2017: No change Alkylating Agents/ May not January 23, Nitrogen Mustards/ prescribe 2017: No Cyclophosphamide change

Ifosfamide Alkylating Agents/ May not January 23, Nitrogen Mustards prescribe 2017: No change Mechlorethamine Alkylating Agents/ May not January 23, Hydrochloride Nitrogen Mustards/ prescribe 2017: No Mechlorethamine (Nitrogen Mustard; change Hn2)

1 Hydrochloride Alkylating Agents/ May not January 23, Nitrogen Mustards/ prescribe 2017: No Melphalan (Phenylalanine Mustard, L- change Pam; L-Phenylalanine Mustard; L- Sarcolysin) Alkylating Agents/ May not January 23, / prescribe 2017: No Carmustine (Bcnu) change

Lomustine (Ccnu) Alkylating Agents/ May not January 23, Nitrosoureas prescribe 2017: No change Streptozocin Alkylating Agents/ May not January 23, Nitrosoureas prescribe 2017: No change (Dtic; Imidazole Alkylating Agents/ May not January 23, Carboxamide) prescribe 2017: No change Anthracenedione May not January 23, prescribe 2017: No change Ado-Trastuzumab Emtansine Antibody-Drug Conjugates May not January 23, prescribe 2017: No change Brentuximab Vedotin Antibody-Drug Conjugates May not January 23, prescribe 2017: No change (For limited / In accordance January 23, purpose of treating psoriasis Folic Acid Antagonists/ with the SCA 2017: No and rheumatoid arthritis only) Methotrexate (Amethopterin; Mtx) (see limitations change on use) Antimetabolites/ May not January 23, Folic Acid Antagonists/ prescribe 2017: No change Antimetabolites/ May not January 23, Folic Acid Antagonists/ prescribe 2017: No change Allopurinol (Antineoplastic) Antimetabolites/ May not January 23, Purine Analogs And Related prescribe 2017: In Agents accordance with the SCA (2- Antimetabolites/ May not January 23, Chlorodeoxyadenosine; Cda) Purine Analogs And Related prescribe 2017: No Agents change

Clofarabine Antimetabolites/ May not January 23, Purine Analogs And Related prescribe 2017: No Agents change

Fludarabine Phosphate Antimetabolites/ May not January 23, Purine Analogs And Related prescribe 2017: No Agents change (6- Antimetabolites/ May not January 23, Mercaptopurine; 6-Mp) Purine Analogs And Related prescribe 2017: In Agents accordance with the SCA

2 (2′- Antimetabolites/ May not January 23, Deoxycoformycin; DCF) Purine Analogs And Related prescribe 2017: No Agents change

Rasburicase Antimetabolites/ May not January 23, Purine Analogs And Related prescribe 2017: No Agents change

Thioguanine (Tg; 6- Antimetabolites/ May not January 23, Thioguanine) Purine Analogs And Related prescribe 2017: No Agents change

Capecitabine Antimetabolites/ May not January 23, Pyrimidine Analogs prescribe 2017: No change Conventional Antimetabolites/ May not January 23, Pyrimidine Analogs prescribe 2017: No change Cytarabine Liposomal Antimetabolites/ May not January 23, Pyrimidine Analogs prescribe 2017: No change Antimetabolites/ May not January 23, Pyrimidine Analogs prescribe 2017: No change (5-Fluorouracil; 5- Antimetabolites/ May not January 23, Fu) Pyrimidine Analogs prescribe 2017: In accordance with the SCA Antimetabolites/ May not January 23, Pyrimidine Analogs prescribe 2017: No change Trifluridine/Tipiracil Antimetabolites/ May not January 23, Pyrimidine Analogs prescribe 2017: No change Antimitotic Agents/ May not January 23, prescribe 2017: No change

Eribulin Mesylate Antimitotic Agents/ May not January 23, Halichondrin B Analog prescribe 2017: No change Antimitotic Agents/ May not January 23, Taxoids prescribe 2017: No change Antimitotic Agents/ May not January 23, Taxoids prescribe 2017: No change (Conventional) Antimitotic Agents/ May not January 23, Taxoids prescribe 2017: No change Paclitaxel Protein-Bound Antimitotic Agents/ May not January 23, Taxoids prescribe 2017: No change Sulfate (Vlb) Antimitotic Agents/ May not January 23, Vinca Alkaloids prescribe 2017: No

3 change Sulfate (Vcr; Lcr) Antimitotic Agents/ May not January 23, Vinca Alkaloids prescribe 2017: No change Vincristine Sulfate Liposome Antimitotic Agents/ May not January 23, Vinca Alkaloids prescribe 2017: No change Tartrate Antimitotic Agents/ May not January 23, Vinca Alkaloids prescribe 2017: No change Citrate Liposomal Antineoplastic Antibiotics/ May not January 23, prescribe 2017: No change Daunorubicin Hydrochloride Antineoplastic Antibiotics/ May not January 23, Anthracyclines prescribe 2017: No change Doxorubicin Hydrochloride Antineoplastic Antibiotics/ May not January 23, Conventional Anthracyclines prescribe 2017: No change Doxorubicin Hydrochloride, Antineoplastic Antibiotics/ May not January 23, Liposomal (Pegylated Anthracyclines prescribe 2017: No Liposomal Doxorubicin) change Hydrochloride Antineoplastic Antibiotics/ May not January 23, Anthracyclines prescribe 2017: No change Hydrochloride Antineoplastic Antibiotics/ May not January 23, Anthracyclines prescribe 2017: No change Antineoplastic Antibiotics/ May not January 23, Anthracyclines prescribe 2017: No change Antineoplastic Antibiotics May not January 23, prescribe 2017: No change (Actinomycin D; Antineoplastic Antibiotics May not January 23, Act) prescribe 2017: No change Mitomycin (Mitomycin-C; Mtc) Antineoplastic Antibiotics May not January 23, prescribe 2017: No change B-Cell Lymphoma-2 Inhibitor May not January 23, prescribe 2017: No change Aldesleukin (Interleukin-2; Il-2) Biological Response Modifiers May not January 23, prescribe 2017: No change Bcg Live Biological Response Modifiers May not January 23, prescribe 2017: In accordance with the SCA Regimens May not January 23, prescribe 2017: No change Amifostine Cytoprotective Agents May not January 23, prescribe 2017: No

4 change Dexrazoxane Cytoprotective Agents May not January 23, prescribe 2017: No change Leucovorin Calcium Cytoprotective Agents/ May not January 23, Leucovorin Calcium (Folinic Acid; prescribe 2017: In Citrovorum Factor) accordance with the SCA Levoleucovorin Cytoprotective Agents May not January 23, prescribe 2017: In accordance with the SCA Mesna Cytoprotective Agents/ May not January 23, Mesna prescribe 2017: In accordance with the SCA Dna Demethylation Agents May not January 23, prescribe 2017: No change Dna Demethylation Agents May not January 23, prescribe 2017: No change Dna Demethylation Agents May not January 23, prescribe 2017: No change (Liposomal) Dna Topoisomerase Inhibitors May not January 23, prescribe 2017: No change Irinotecan Hydrochloride Dna Topoisomerase Inhibitors May not January 23, (Conventional) prescribe 2017: No change Hydrochloride Dna Topoisomerase Inhibitors/ May not January 23, Topotecan prescribe 2017: No change (Erwinia) Enzymes May not January 23, prescribe 2017: No change (Peg-L- Enzymes May not January 23, Asparaginase) prescribe 2017: No change (Vp-16, Vp-16-213) Epipodophyllotoxins/ May not January 23, Podophyllotoxin Derivatives/ prescribe 2017: No Etoposide (Vp-16, Vp-16-213) change

Etoposide Phosphate (Vp-16, Epipodophyllotoxins/ May not January 23, Vp-16-213) Injection Podophyllotoxin Derivatives/ prescribe 2017: No Etoposide (Vp-16, Vp-16-213) change

Teniposide (Vm-26) Epipodophyllotoxins/ May not January 23, Podophyllotoxin Derivatives prescribe 2017: No change Histone Deacetylase Inhibitors May not January 23, prescribe 2017: No change

5 Histone Deacetylase Inhibitors May not January 23, prescribe 2017: No change Histone Deacetylase Inhibitors May not January 23, prescribe 2017: No change Histone Deacetylase Inhibitors May not January 23, prescribe 2017: No change Abiraterone Acetate Hormones/ In accordance January 23, Antiandrogens with the SCA 2017: No change Bicalutamide Hormones/ In accordance January 23, Antiandrogens with the SCA 2017: No change Enzalutamide Hormones/ In accordance January 23, Antiandrogens with the SCA 2017: No change Flutamide Hormones/ In accordance January 23, Antiandrogens with the SCA 2017: No change Nilutamide Hormones/ In accordance January 23, Antiandrogens with the SCA 2017: No change Fulvestrant Hormones/ In accordance January 23, Antiestrogens with the SCA 2017: No change Tamoxifen Hormones/ In accordance January 23, Antiestrogens with the SCA 2017: No change Toremifene Hormones/ In accordance January 23, Antiestrogens with the SCA 2017: No change Anastrozole Hormones/ In accordance January 23, Aromatase Inhibitors with the SCA 2017: No change Exemestane Hormones/ In accordance January 23, Aromatase Inhibitors with the SCA 2017: No change Letrozole Hormones/ In accordance January 23, Aromatase Inhibitors with the SCA 2017: No change Goserelin Acetate Hormones/ In accordance January 23, Gonadotropin-Releasing Hormone with the SCA 2017: No Analog change

Histrelin Acetate Hormones/ May not January 23, Gonadotropin-Releasing Hormone prescribe 2017: No Analog change

Leuprolide Acetate Hormones/ In accordance January 23, Gonadotropin-Releasing Hormone with the SCA 2017: No Analog change

Leuprolide Acetate And Hormones/ In accordance January 23,

6 Norethindrone Acetate Gonadotropin-Releasing Hormone with the SCA 2017: No Analog/ change Progestin Combination Triptorelin Hormones/ May not January 23, Gonadotropin-Releasing Hormone prescribe 2017: No Analog change

Medroxyprogesterone Acetate Hormones/ May not January 23, (Cross-Reference) Progestins (Cross-reference) prescribe 2017: No change Megestrol Acetate (Cross- Hormones/ May not January 23, Reference) Progestins (Cross-reference) prescribe 2017: No change Imidazotetrazine Derivatives May not January 23, prescribe 2017: No change Dabrafenib Kinase Inhibitors/ May not January 23, BRAF Inhibitors prescribe 2017: No change Vemurafenib Kinase Inhibitors/ May not January 23, BRAF Inhibitors prescribe 2017: No change Kinase Inhibitors/ May not January 23, Cyclin-Dependent Kinase prescribe 2017: No Inhibitors change

Ruxolitinib Kinase Inhibitors/ In accordance January 23, Janus-Associated Kinase Inhibitors with the SCA 2017: No change Cobimetinib Kinase Inhibitors/ May not January 23, MEK Inhibitors prescribe 2017: No change Trametinib Kinase Inhibitors/ May not January 23, MEK Inhibitors prescribe 2017: No change Everolimus Kinase Inhibitors/ In accordance January 23, mTOR Inhibitors with the SCA 2017: No change Temsirolimus Kinase Inhibitors/ May not January 23, mTOR Inhibitors prescribe 2017: No change Regorafenib Kinase Inhibitors/ May not January 23, Multikinase Inhibitor prescribe 2017: No change Sorafenib Kinase Inhibitors/ May not January 23, Multikinase Inhibitor prescribe 2017: No change Idelalisib Kinase Inhibitors/ May not January 23, Phosphatidylinositol 3-Kinase prescribe 2017: No Inhibitors change

Afatinib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No change Alectinib Kinase Inhibitors/ May not January 23,

7 Tyrosine Kinase Inhibitors prescribe 2017: No change Axitinib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No change Bosutinib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No change Cabozantinib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No change Ceritinib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No change Crizotinib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No change Dasatinib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No change Erlotinib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No change Gefitinib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No change Ibrutinib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No change Imatinib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No change Lapatinib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No change Lenvatinib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No change Nilotinib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No change Osimertinib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No change Pazopanib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No change Ponatinib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No change Sunitinib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No change Vandetanib Kinase Inhibitors/ May not January 23, Tyrosine Kinase Inhibitors prescribe 2017: No

8 change Hydrochloride (N- Methylhydrazine Derivatives May not January 23, Methylhydrazine; Mih) prescribe 2017: No change Miscellaneous Antineoplastics May not January 23, prescribe 2017: No change (O,P′-DDD) Miscellaneous Antineoplastics May not January 23, prescribe 2017: No change Miscellaneous Antineoplastics May not January 23, prescribe 2017: No change Sipuleucel-T Miscellaneous Antineoplastics May not January 23, prescribe 2017: No change Sonidegib Miscellaneous Antineoplastics May not January 23, prescribe 2017: No change Sterile Talc Powder Miscellaneous Antineoplastics May not January 23, prescribe 2017: No change Miscellaneous Antineoplastics May not January 23, prescribe 2017: No change Vismodegib Miscellaneous Antineoplastics May not January 23, prescribe 2017: No change Alemtuzumab Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Atezolizumab Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Bevacizumab Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Blinatumomab Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Cetuximab Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Daratumumab Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Dinutuximab Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Elotuzumab Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Ibritumomab Tiuxetan Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change

9 Ipilimumab Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Necitumumab Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Nivolumab Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Obinutuzumab Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Ofatumumab Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Olaratumab Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Panitumumab Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Pertuzumab Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Ramucirumab Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Trastuzumab Monoclonal Antibodies May not January 23, (Antineoplastic) prescribe 2017: No change Talimogene Laherparepvec Oncolytic Virus May not January 23, prescribe 2017: No change Parp Enzymes Inhibitor May not January 23, prescribe 2017: No change Platinum Coordination Complex May not January 23, prescribe 2017: No change (Cddp) Platinum Coordination Complex May not January 23, prescribe 2017: No change Platinum Coordination Complex May not January 23, prescribe 2017: No change Proteasome Inhibitors May not January 23, prescribe 2017: No change Proteasome Inhibitors May not January 23, prescribe 2017: No change Proteasome Inhibitors May not January 23,

10 prescribe 2017: No change Omacetaxine Mepesuccinate Protein Synthesis Inhibitor May not January 23, prescribe 2017: No change Radium Ra 223 Dichloride Radiopharmaceuticals May not January 23, prescribe 2017: No change Samarium Sm 153 Lexidronam Radiopharmaceuticals May not January 23, prescribe 2017: No change Sodium Iodide I 131 Radiopharmaceuticals May not January 23, (Therapeutic) prescribe 2017: No change Strontium-89 Chloride Radiopharmaceuticals May not January 23, prescribe 2017: No change (All-Trans-Retinoic (Antineoplastic) May not January 23, Acid) prescribe 2017: No change (Oral) Rexinoids (Oral) May not January 23, prescribe 2017: No change Hydroxyurea Substituted Ureas May not January 23, prescribe 2017: In accordance with the SCA Ziv-Aflibercept Vascular Endothelial Growth May not January 23, Factor prescribe 2017: No change

11